

Fund manager:



Co-manager:



Monthly Factsheet


Econopolis Global Equity Fund

Description of funds

Econopolis Global Equity is a compartment of Econopolis Funds SICAV, a Luxembourg UCITS fund. The fund aims to deliver a long term return to investors via investments in equity and monetary instruments, without geographical restriction and without restrictions concerning sector or currency allocation. Econopolis Global Equity is aimed at investors with an investor horizon of more than 5


Comments of portfolio manager

Global lost around 6% in February. The shares market underwent a significant correction because investors were concerned about the economic consequences of the corona virus outbreak. We took profits in Umicore because the value of the share had increased considerably. We sold our position in Nokia because the company is still struggling. We slightly reduced positions in Arkema, Alphabet, Arista Networks, Becton Dickinson, Booking Holdings, Kion, Microsoft, Orpea and Vopak. Biopharma companies Argen-X and UCB were newcomers within the compartment. We also took new positions in ABB, Assa Abloy and Bureau Veritas. The Swedish/Swiss ABB is one of the biggest players in automation, robotics and electrification. As a result of the sale of its electricity networks, ABB will be able to grow more quickly and realise higher margins. Most of the income from this sale (11 billion dollars), will be used to buy its own shares. Assa Abloy is a world leader in locks and security solutions. The group is aiming for annual growth of 10% (including acquisitions) combined with operating margin of 16-17%. The underlying factors for growth are urbanisation and the transition to smarter and more advanced locking solutions and access systems. Assa Abloy has a strong market position in developed markets and a relatively defensive profile. Bureau Veritas is a world leader in test, inspection and certification services. The company has a relatively defensive profile. We increased our existing positions in NN Group and Tencent.



Disclaimer: the graph illustrates the past performance of the fund. Past performance does not offer any guarantee for future performance. The performance is net of cost and fees. The fund was launched in August 2015. The performance is calculated in euro. Standard deviation and Sharpe ratio are calculated on a weekly basis, over a 3 year period.


Geografic overview positions






Econopolis Global Equity Fund







Stocks - Top 10	Currency	Industry	% of total
Roche Holding AG	CHF	Health Care	3,99%
PepsiCo Inc	USD	Consumer Staples	3,41%
Alphabet Inc	USD	Communication Services	3,38%
NN Group NV	EUR	Financials	3,28%
Arkema SA	EUR	Materials	3,25%
Activision Blizzard Inc	USD	Communication Services	3,24%
Orpea	EUR	Health Care	3,14%
Yara International ASA	NOK	Materials	3,13%
Varian Medical Systems Inc	USD	Health Care	3,07%
Becton Dickinson and Co	USD	Health Care	2,97%

Total positions

40

Key facts and practical information

Compartment of: Econopolis Funds, SICAV under

Luxembourg law with European Passport

Risk profile: 1 - 2 - 3 - 4 - 5 - 6 - 7

Investment horizon: 5 year

Launch date: August 2015

Currency: EUR

Shares: Capitalisation & Distribution

ISIN-code I-class Capitalisation: LU1248447622
ISIN-code I-class Distribution: LU1248447978
Size: FUR 15.7 mln.

Size: EUR 15,7 mln.

Subscription fee: Max. 3% dependant on distributor Redemption fee: Max. 3% dependant on distributor

Subscription and redemption: Daily before 12:00pm

Management fee: 0,85%
Total expense ratio I-Kapitalisatie: 1,41%
Total expense ratio I-Distributie: 1,41%
Performance fee: NA

 $NAV-reporting: \quad www.fundsquare.net/homepage,$

Bloomberg, Reuters, ...

Licensed in: Belgium, Luxembourg, Switzerland

Geographical allocation fund



Warning:

The compartment is approved for distribution in Belgium, Luxembourg and Switzerland. The prospectus and essential investor information, KIID, are available on the website www.fundsquare.net/homepage, where the net asset value is also published. This document is a general document for the general public and is not based on information of the personal situation of the reader. There is no review of the knowledge and experience, neither of his financial situation of investment objectives. There are possibly financial instrument mentioned in this document that are not suitable nor appropriate for the reader. Therefore the document exclusively contains product information of the mentioned financial instrument and cannot be considered as investment advice.

Contact